Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ticaloguard
- Development stage
- Unknown
- Lead developer
- Cairo University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ticagrelor is a small molecule antiplatelet agent that acts as a selective and reversible P2Y12 receptor antagonist. It prevents adenosine diphosphate (ADP)-mediated P2Y12-dependent platelet aggregation. This specific entry refers to a clinical evaluation conducted by Cairo University to compare the therapeutic efficacy and safety of the generic formulation, Ticaloguard (manufactured by Marcyrl Pharmaceutical Industries), against the reference brand Brilique (AstraZeneca). While the primary indication for ticagrelor is the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), this specific study was a pilot trial performed in healthy volunteers to establish clinical equivalence beyond standard bioequivalence.
- Brand names
- Ticaloguard
- Other names
- ticagrelor
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on Ticaloguard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ticaloguard.